Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Epstein

Internal Medicine Indian Orchard, MA Medical Doctor

NPI 1265443816 CMS profile 102068

811 Worcester St, Indian Orchard, MA 01151

Open in the dashboard

General payments

$12,129

699 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Epstein of Indian Orchard, MA is reported in the CMS Open Payments database as having received $12,129 across 699 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,723 88
2024 General $1,840 99
2023 General $2,148 115
2022 General $1,649 97
2021 General $1,894 111
2020 General $1,336 81
2019 General $1,540 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Epstein
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kevin Epstein were reported at $1,723. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kevin Epstein Internal Medicine median Middle half National median
2019 $1,540 $159 $48–$570 $163
2020 $1,336 $119 $33–$402 $114
2021 $1,894 $135 $37–$521 $132
2022 $1,649 $141 $42–$496 $149
2023 $2,148 $149 $45–$519 $160
2024 $1,840 $154 $47–$537 $164
2025 $1,723 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,962 100 payments
  2. Pfizer Inc. $1,504 116 payments
  3. Novo Nordisk Inc $1,297 72 payments
  4. Lilly USA, LLC $1,192 67 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $842 49 payments
  6. GlaxoSmithKline, LLC. $689 41 payments
  7. Abbott Laboratories $588 28 payments
  8. Merck Sharp & Dohme Corporation $545 33 payments
  9. Janssen Pharmaceuticals, Inc $502 31 payments
  10. Exact Sciences Corporation $473 25 payments
  11. Other $2,536 137 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,073 695 payments
  2. Education $56 4 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $1,020 76 payments
  2. Ozempic $919 50 payments
  3. FARXIGA $770 39 payments
  4. TRELEGY ELLIPTA $662 39 payments
  5. RYBELSUS $660 34 payments
  6. XARELTO $487 30 payments
  7. FreeStyle Libre 3 $471 22 payments
  8. MOUNJARO $470 27 payments
  9. JARDIANCE $468 26 payments
  10. COLOGUARD DNA CAPTURE REAGENTS $436 27 payments
  11. Other $9,922 618 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 97 drugs

Part D claims

5,651

Median for Internal Medicine: 777

Drug cost

$431,978

Median for Internal Medicine: $73,373

Branded share of claims

15.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 66 $74,110
Eliquis Apixaban Brand 79 $64,871
Januvia Sitagliptin Phosphate Brand 39 $47,062
Mounjaro Tirzepatide Brand 42 $44,896
Trulicity Dulaglutide Brand 28 $42,008
Rybelsus Semaglutide Brand 18 $29,418
Ozempic Semaglutide Brand 18 $26,684
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 16 $22,510
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $7,674
Atorvastatin Calcium Generic 523 $7,607

The 10 drugs with the highest cost, of 97 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$68,832

Medicare's payments for the services billed

Medicare patients

276

Average age 75

Services billed

1,167

142 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 39%
Diabetes 22%
Cancer 19%
Ischemic heart disease 18%
Chronic kidney disease 18%
Depression 17%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $131
  • Lilly USA, LLC $120
$250 66 —
MOUNJARO
  • Lilly USA, LLC $162
$162 42 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $127
$127 12 —
AREXVY
  • GlaxoSmithKline, LLC. $113
$113 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $110
$110 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

699 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record